|
Financial Information Relating to Reportable Segments (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | |
|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
|
| Segment Reporting Information [Line Items] | ||
| External sales | $ 85,668 | $ 75,025 |
| Earnings before income taxes | 39,654 | 37,986 |
|
Reportable Segment
|
||
| Segment Reporting Information [Line Items] | ||
| External sales | 85,668 | 75,025 |
| Earnings before income taxes | 41,663 | 39,097 |
|
Reportable Segment | Biotechnology
|
||
| Segment Reporting Information [Line Items] | ||
| External sales | 73,190 | 69,503 |
| Earnings before income taxes | 39,378 | 36,994 |
|
Reportable Segment | Clinical Controls
|
||
| Segment Reporting Information [Line Items] | ||
| External sales | 12,478 | 5,522 |
| Earnings before income taxes | 2,285 | 2,103 |
|
Unallocated Amount to Segment
|
||
| Segment Reporting Information [Line Items] | ||
| Earnings before income taxes | $ (2,009) | $ (1,111) |